An official document from the Congressional Research Service confirms that in 2019 India was terminated from the Generalized System of Preferences.
According to the 2019 National Trade Estimate Report, under foreign trade barriers of India’s Department of Pharmaceuticals and National Pharmaceutical Pricing Authority (NPPA), an order was to cap prices on coronary stents such as cardiac stents and knee implants under medical device price control. The U.S. companies have raised significant concerns with these actions of India on price caps. The report also added the data localization requirements and barriers for electronic commerce. (Ref Page no:- 244)